Loading
Life sciences · Journal article
Diabetology & Metabolic Syndrome · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This study aimed to determine the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) in community-dwelling Turkish adults aged ≥ 65 years with at least one cardiometabolic risk factor (CMRF) and to identify risk factors associated with liver fibrosis. This nationwide study is a retrospective cross-sectional analysis of prospectively collected data from 31 cities and 44 internal medicine outpatient clinics representing all statistical regions of Türkiye. A total of 2613 older individuals (mean age 71.55 ± 5.40, 62.8% female) were enrolled in the study. The prevalence of MASLD ( N = 1811) and high FIB-4 ( N = 412) was 69.3% and 15.8% in the all patient group, respectively. The mean FIB-4 score was significantly lower in MASLD group ( P < 0.001). The prevalence of smoking (8.7%, P = 0.034), type 2 diabetes mellitus (T2DM) (54.4%, P < 0.001), metabolic syndrome (83.7%, P < 0.001), obesity (42.2%, P = 0.004), dyslipidemia (45.6%, P = 0.001) and MASLD (59.2%, P < 0.001) was found to be lower in the high FIB-4 group. Moreover, the prevalence of high FIB-4 progressively decreased with the number of CMRFs, ranging from 35.9% in participants with one factor to 13.3% in those with all five factors. In the multivariable regression analysis; female sex [OR: 0.763, (95%CI: 0.605–0.961); ( P = 0.022), smoking [0.610, (95%CI: 0.419–0.889); ( P = 0.010)], T2DM [OR: 0.722, (95%CI: 0.575–0.905); P = 0.005], MASLD [OR: 0.671, (95%CI: 0.533–0.844); ( P = 0.001)] were independently and negatively associated with high FIB-4 score. Despite high MASLD prevalence in older Turkish adults, the FIB-4 score negatively correlates with CMRFs, rendering it unreliable. These findings suggest that FIB-4 may be driven by age and age-related changes rather than liver pathology in this population, significantly limiting its utility as a screening tool in geriatric care.